Publication

Integrated Traditional Chinese Medicine Improves Functional Outcome in Acute Ischemic Stroke: From Clinic to Mechanism Exploration With Gut Microbiota

Downloadable Content

Persistent URL
Last modified
  • 05/20/2025
Type of Material
Authors
    Qian Guo, Xuanwu Hospital, Capital Medical UniversityCan Ni, Xuanwu Hospital, Capital Medical UniversityLinjing Li, Beijing Chaoyang Integrative Medicine Emergency Medical CenterMo Li, State Key Laboratory for Turbulence & Complex SystemXiaoqing Jiang, State Key Laboratory for Turbulence & Complex SystemLi Gao, Xuanwu Hospital, Capital Medical UniversityHuaiqiu Zhu, Emory UniversityJuexian Song, Xuanwu Hospital, Capital Medical University
Language
  • English
Date
  • 2022-02-09
Publisher
  • Emory University Libraries
Publication Version
Copyright Statement
  • © 2022 Guo, Ni, Li, Li, Jiang, Gao, Zhu and Song
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 12
Start Page
  • 827129
End Page
  • 827129
Grant/Funding Information
  • This work was supported by the National Key Research and Development Program of China (2021YFC2300300), the Science and Technology Program of Beijing (Z171100001717012), the Key Special Project of Ministry of Science and Technology Research on modernization of Traditional Chinese Medicine (2019YFC1712400), and the National Natural Science Foundation of China (32070667, 31671366).
Supplemental Material (URL)
Abstract
  • As a life-threatening disease, stroke is the leading cause of death and also induces adult disability worldwide. To investigate the efficacy of the integrated traditional Chinese medicine (ITCM) on the therapeutic effects of acute ischemic stroke (AIS) patients, we enrolled 26 patients in the ITCM [Tanhuo decoction (THD) + Western medicine (WM)] group and 23 in the WM group. Thirty healthy people were also included in the healthy control (HC) group. ITCM achieved better functional outcomes than WM, including significant reduction of the phlegm-heat syndrome and neurological impairment, and improvement of ability. These facts were observed in different pretreatment gut enterotypes. In this paper, we collected the stool samples of all participants and analyzed the 16S rRNA sequence data of the gut microbiota. We identified two enterotypes (Type-A and Type-B) of the gut microbial community in AIS samples before treatment. Compared to Type-B, Type-A was characterized by a high proportion of Bacteroides, relatively high diversity, and severe functional damage. In the ITCM treatment group, we observed better clinical efficacy and positive alterations in microbial diversity and beneficial bacterial abundance, and the effect of approaching healthy people’s gut microbiota, regardless of gut enterotypes identified in pretreatment. Furthermore, we detected several gut microbiota as potential therapeutic targets of ITCM treatment by analyzing the correlations between bacterial abundance alterations and functional outcomes, where Dorea with the strongest correlation was known to produce anti-inflammatory metabolite and negatively linked to trimethylamine-N-oxide (TMAO), a biomarker of AIS. This study analyzed clinical and gut microbial data and revealed the possibility of a broad application independent of the enterotypes, as well as the therapeutic targets of the ITCM in treating AIS patients with phlegm-heat syndrome.
Author Notes
Keywords
Research Categories
  • Engineering, Biomedical

Tools

Relations

In Collection:

Items